IMMP

Immutep Limited

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$3.66

Price (1 Year)

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %8.1 / %30

Non-compliant assets / Total market cap %8.1 / %30

Non-compliant revenue / Total income %11.1 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer.

Website

Analysis (Turkish): IMMP Hissesi Caiz mi, Helal mi? Immutep Limited Katılım Analizi